Subscribe to KPMG's Deal Capsule Life Sciences Newsletter
Preview of the KPMG Deal Capsule Life Sciences Newsletter
The new edition of our quarterly newsletter on transactions in the global life sciences industry, glances back at the significant deals that took place in H1 2021.
Driven by a key role in combating COVID-19 and future topics such as digital health, life sciences M&A activity reaches an all-time high in the first half of 2021.
- In H1 2021, deal activity remains strong mainly driven by biotech and medical devices & diagnostics.
- The M&A focus shifted from pharmaceuticals to biotech, which came to surface latest since the outbreak of COVID-19 and was amplified over the last quarters.